Price (delayed)
$54.82
Market cap
$5.05B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.22
Enterprise value
$4.61B
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of
There are no recent dividends present for RARE.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.